美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

百济神州

230.98

+2.841.24%

盘后：229.75-1.0150-0.44%17:21 EDT

成交量：51.99万

成交额：1.20亿

市值：248.81亿

市盈率：-37.72

高：234.15

开：229.30

低：227.40

收：228.14

数据加载中...

总览公司新闻公告

百济神州：2024年度净利润约-49.78亿元

每日经济新闻

百济神州2024年业绩快报：归母净利润亏损49.78亿元

百济神州盘前涨超3%，2025年营业收入预计将介于352亿元至381亿元之间

老虎资讯综合

百济神州：2024年净利润亏损49.78亿元，2025年营收预计352亿至381亿元

百济神州：2025年营业收入预计将介于人民币352亿元至381亿元之间

每日经济新闻

百济神州：2025年营业收入预计将介于人民币352亿元至381亿元之间

百济神州 2024年第四季度 GAAP 每股亏损为1.43美元，同比上升自3.53美元，销售额为11.3亿美元，相比去年同期为6.3441亿美元

百济神州距离默沙东，差了4个恒瑞医药

百济神州CFO黄智确认离任

百济神州CFO黄智确认离任

百济神州原大中华区CFO离职，任内完成科创板IPO

百济神州回应原大中华区CFO离职：将尽快启动其继任者的招聘

230元/股！百济神州股价再创新高

百济神州回应原大中华区CFO离职：将尽快启动其继任者的招聘

每日经济新闻

百济神州确认原大中华区首席财务官兼全球技术运营财务负责人黄智离职

南方财经网

百济神州大中华区CFO黄智已经离职

百济神州大中华区CFO黄智已经离职

港股概念追踪|百济神州成为国内“创新药一哥” 机构看好创新药2025年估值修复（附概念股）

【创新药板块大幅走高君实生物等多股涨超10%】百济神州涨近4%，创历史新高，君实生物、博瑞医药、益方生物涨超10%，诺诚健华、新诺威、荣昌生物、昭衍新药等多股涨逾5%。消息面上，据统计，2024年全年创新药企License-out交易首付款总额（31.6亿美元）甚至超过了创新药研发融资的总额（27.1亿美元），创新药出海成为国内创新药企核心动力。

创新药企业业绩有望显著改善，诺诚健华、百济神州等被机构推荐

中国制药网

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/ONC/news?page=8"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百济神州","latestPrice":230.98,"timestamp":1744920000000,"preClose":228.14,"halted":0,"volume":519865,"hourTrading":{"tag":"盘后","latestPrice":229.75,"preClose":230.765,"latestTime":"17:21 EDT","volume":54100,"amount":12495855.13,"timestamp":1744924915084},"delay":0,"floatShares":79387510,"shares":107719405,"eps":-6.124009,"marketStatus":"休市中","change":2.84,"latestTime":"04-17 16:00:00 EDT","open":229.3,"high":234.15,"low":227.3961,"amount":119885584.17555,"amplitude":0.029604,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-6.124009,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":228.14,"preHourTrading":{"tag":"盘前","latestPrice":233.81,"preClose":228.14,"latestTime":"08:41 EDT","volume":73,"amount":17065.739250000002,"timestamp":1744893686762},"postHourTrading":{"tag":"盘后","latestPrice":229.75,"preClose":230.765,"latestTime":"17:21 EDT","volume":54100,"amount":12495855.13,"timestamp":1744924915084},"volumeRatio":0.7116059393545304,"impliedVol":0.529,"impliedVolPercentile":0.8767},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":79387510,"roa":"-6.07%","roe":"-18.77%","lyrEps":-6.124009,"volumeRatio":0.7116059393545304,"shares":107719405,"dividePrice":0,"high":234.15,"amplitude":0.029604,"preClose":228.14,"low":227.3961,"week52Low":126.9681,"pbRate":"7.47","psRate":"6.53","week52High":287.88,"institutionHeld":0,"latestPrice":230.98,"eps":-6.124009,"divideRate":0,"volume":519865,"delay":0,"ttmEps":-6.124009,"open":229.3,"prevYearClose":184.71,"prevWeekClose":230.36,"prevMonthClose":272.17,"prevQuarterClose":272.17,"fiveDayClose":208.31,"twentyDayClose":262.59,"sixtyDayClose":222.22,"earningDate":1746547200000,"earningTime":"盘前"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:8,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514808241","title":"百济神州：2024年度净利润约-49.78亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514808241","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514808241?lang=zh_cn&edition=fundamental","pubTime":"2025-02-27 19:26","pubTimestamp":1740655580,"startTime":"0","endTime":"0","summary":"每经AI快讯，百济神州 2月27日晚间发布2024年度业绩快报，营业收入约272.14亿元，同比增加56.2%；归属于上市公司股东的净利润亏损约49.78亿元；基本每股收益亏损3.64元。上年同期营业收入约174.23亿元；归属于上市公司股东的净利润亏损约67.16亿元；基本每股收益亏损4.95元。截至发稿，百济神州市值为3150亿元。道达号“个股趋势”提醒：1. 近30日内无机构对百济神州-U进行调研。应届生求职免费住15天！开年就爆满，记者探访：单间标配独立卫浴+WiFi+空调","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022719453596327ebb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022719453596327ebb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC"],"gpt_icon":0},{"id":"2514014870","title":"百济神州2024年业绩快报：归母净利润亏损49.78亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514014870","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514014870?lang=zh_cn&edition=fundamental","pubTime":"2025-02-27 19:25","pubTimestamp":1740655533,"startTime":"0","endTime":"0","summary":"2月27日，百济神州（688235/06160/BGNE）发布公告，2024年度主要财务数据为初步核算数据，未经审计。报告期内，公司营业总收入为272.14亿元，较上年同期增长56.2%，其中产品收入为269.94亿元，同比上升74.1%。归母净利润约亏损49.78亿元，相较上年同期的亏损67.2亿元有所改善。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502273331847050.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ONC","06160"],"gpt_icon":0},{"id":"1155687917","title":"百济神州盘前涨超3%，2025年营业收入预计将介于352亿元至381亿元之间","url":"https://stock-news.laohu8.com/highlight/detail?id=1155687917","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155687917?lang=zh_cn&edition=fundamental","pubTime":"2025-02-27 19:19","pubTimestamp":1740655173,"startTime":"0","endTime":"0","summary":"2月27日，百济神州盘前涨超3%，公司公告称，2025年营业收入预计将介于人民币352亿元至381亿元之间，收入强劲增长的预期主要受益于百悦泽®在美国的领先地位以及在欧洲和全球其他重要市场的持续扩张；同时基于公司产品组合和生产效率的提高，预计2025年毛利率将处于80%至90%的中位区间。预计2025年研发费用、销售及管理费用合计将介于人民币295亿元至319亿元之间。","market":"us","thumbnail":"https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC","06160"],"gpt_icon":0},{"id":"2514805990","title":"百济神州：2024年净利润亏损49.78亿元，2025年营收预计352亿至381亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514805990","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514805990?lang=zh_cn&edition=fundamental","pubTime":"2025-02-27 19:19","pubTimestamp":1740655140,"startTime":"0","endTime":"0","summary":"2月27日晚间，百济神州有限公司发布业绩快报，2024年实现营业总收入272.14亿元，同比增长56.2%；归属于母公司所有者的净利润亏损49.78亿元，上年同期亏损67.16亿元。报告期内，公司营业收入增加56.2%，主要得益于百悦泽，以及安进授权产品和百泽安的销售增长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227194655abdf3b66&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227194655abdf3b66&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC"],"gpt_icon":0},{"id":"2514487777","title":"百济神州：2025年营业收入预计将介于人民币352亿元至381亿元之间","url":"https://stock-news.laohu8.com/highlight/detail?id=2514487777","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514487777?lang=zh_cn&edition=fundamental","pubTime":"2025-02-27 19:12","pubTimestamp":1740654779,"startTime":"0","endTime":"0","summary":"每经AI快讯，2月27日，百济神州公告，2025年营业收入预计将介于人民币352亿元至381亿元之间，收入强劲增长的预期主要受益于百悦泽?在美国的领先地位以及在欧洲和全球其他重要市场的持续扩张；同时基于公司产品组合和生产效率的提高，预计2025年毛利率将处于80%至90%的中位区间。预计2025年研发费用、销售及管理费用合计将介于人民币295亿元至319亿元之间。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202502273331839278.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502273331839278.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ONC","06160"],"gpt_icon":0},{"id":"2514774288","title":"百济神州：2025年营业收入预计将介于人民币352亿元至381亿元之间","url":"https://stock-news.laohu8.com/highlight/detail?id=2514774288","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514774288?lang=zh_cn&edition=fundamental","pubTime":"2025-02-27 19:10","pubTimestamp":1740654654,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1500","BK1588","BK1161","LU0588546209.SGD","688235","LU1969619763.USD","BK1583","ONC","06160","BK4139","LU0307460666.USD","LU2328871848.SGD","BK0239"],"gpt_icon":0},{"id":"1123333578","title":"百济神州 2024年第四季度 GAAP 每股亏损为1.43美元，同比上升自3.53美元，销售额为11.3亿美元，相比去年同期为6.3441亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1123333578","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123333578?lang=zh_cn&edition=fundamental","pubTime":"2025-02-27 19:07","pubTimestamp":1740654422,"startTime":"0","endTime":"0","summary":"百济神州报告季度每股亏损为1.43美元。这较去年同期的每股亏损3.53美元增加了59.49%。公司报告季度销售额为11.3亿美元，未达分析师预期的74.2亿美元，差距84.80%。以上内容来自Benzinga Earnings专栏，原文如下：BeiGene  reported quarterly losses of $ per share. This is a 59.49 percent increase over losses of $ per share from the same period last year.  The company reported quarterly sales of $1.13 billion which missed the analyst consensus estimate of $7.42 billion by 84.80 percent.  This is a 77.78 percent increase over sales of $634.41 million the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"百济神州 2024年第四季度 GAAP 每股亏损为1.43美元，同比上升自3.53美元，销售额为11.3亿美元，相比去年同期为6.3441亿美元","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC","06160"],"gpt_icon":1},{"id":"2514887138","title":"百济神州距离默沙东，差了4个恒瑞医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2514887138","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514887138?lang=zh_cn&edition=fundamental","pubTime":"2025-02-27 18:11","pubTimestamp":1740651093,"startTime":"0","endTime":"0","summary":"直到近期，百济神州以3100余亿元的A股市值暂时超越恒瑞医药，这场“医药一哥”的易主才引起短暂讨论。百济神州60%收入来自海外，而恒瑞医药仍然依赖国内市场。此次市值跃迁的核心驱动力，源自百济神州打造的核心产品“泽布替尼”。泽布替尼在2024年前三季度的销售额为18.2亿美元。默沙东的“Keytruda”，以294.8亿美元销售额蝉联“药王”，覆盖40个肿瘤适应症。百济神州现有管线中，约90%聚焦于肿瘤治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/251845","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["IE00BFTCPJ56.SGD","BK4559","MRK","IE00BJJMRZ35.SGD","LU1023059063.AUD","LU0208291251.USD","LU0203345920.USD","LU1057294990.SGD","LU2361045086.USD","SG9999002224.SGD","IE0002141913.USD","LU1585245621.USD","LU1989771016.USD","LU1093756168.USD","LU1061106388.HKD","LU1571399168.USD","LU0965509283.SGD","LU1917777945.USD","LU1983299246.USD","LU1989772923.USD","LU1934455277.USD","LU1941712348.USD","LU0985320562.USD","LU1066051498.USD","LU2468319806.SGD","BK4533","SG9999015341.SGD","LU1037948541.HKD","LU0265550359.USD","LU2328871848.SGD","ONC","LU0588546209.SGD","LU1116320737.USD","IE00BBT3K403.USD","IE00BJT1NW94.SGD","LU1093756325.SGD","LU2023250504.SGD","SG9999001176.SGD","LU0265550946.USD","IE00BSNM7G36.USD","LU0266013472.USD","SG9999015358.SGD","06160","LU0203347892.USD","LU1037948897.HKD","SG9999014575.USD","SG9999014559.SGD","LU0320765489.SGD","LU0234572021.USD","BK4588"],"gpt_icon":1},{"id":"2514848126","title":"百济神州CFO黄智确认离任","url":"https://stock-news.laohu8.com/highlight/detail?id=2514848126","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514848126?lang=zh_cn&edition=fundamental","pubTime":"2025-02-27 11:27","pubTimestamp":1740626870,"startTime":"0","endTime":"0","summary":"2月26日，百济神州（688235）向多家媒体确认其大中华区首席财务官（CFO）兼全球技术运营财务负责人黄智（EricHuang）已离任，公司将尽快启动继任者招聘程序。黄智于2020年10月加入百济神州，此前曾在诺华集团（2007-2020年）担任多个财务管理职务，包括诺华韩国国家首席财务官，主导过组织架构优化及合规体系建设。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502273331382666.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1588","BK4139","LU2328871848.SGD","BK1500","06160","BK1161","LU0307460666.USD","LU1969619763.USD","ONC","BK1583","LU0588546209.SGD"],"gpt_icon":0},{"id":"2514817092","title":"百济神州CFO黄智确认离任","url":"https://stock-news.laohu8.com/highlight/detail?id=2514817092","media":"财中社","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514817092?lang=zh_cn&edition=fundamental","pubTime":"2025-02-27 11:26","pubTimestamp":1740626760,"startTime":"0","endTime":"0","summary":"2月26日，百济神州向多家媒体确认其大中华区首席财务官兼全球技术运营财务负责人黄智已离任，公司将尽快启动继任者招聘程序。在任期间，黄智主导了百济神州2021年12月的科创板IPO，该公司以192.60元/股的发行价登陆A股，募资221.6亿元，成为全球首家在三地上市的生物科技企业。财务数据显示，2024年前三季度百济神州营收达191.36亿元，同比增长48.6%。值得注意的是，这不是百济神州近三年第一次CFO变动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022711270998945549&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022711270998945549&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","06160","688235","BK0239"],"gpt_icon":0},{"id":"2514188905","title":"百济神州原大中华区CFO离职，任内完成科创板IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2514188905","media":"界面","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514188905?lang=zh_cn&edition=fundamental","pubTime":"2025-02-26 17:17","pubTimestamp":1740561457,"startTime":"0","endTime":"0","summary":"界面新闻记者 |唐卓雅界面新闻编辑 |谢欣2月26日，百济神州向界面新闻记者确认，百济神州原大中华区首席财务官兼全球技术运营财务负责人黄智于近日离任寻求外部发展机会。2020年10月，黄智加入百济神州，担任大中华区首席财务官兼全球技术运营财务负责人，同时领导亚太地区财务计划和分析工作。百济神州发行价为192.60元/股，在科创板上市发行股份总数为普通股1.15亿股，募集资金总额221.60亿元。黄智在百济神州任职期间，百济神州逐渐减亏。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226171805a254a5c6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226171805a254a5c6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1500","LU0588546209.SGD","ONC","06160","LU1969619763.USD","LU0307460666.USD","BK1161","BK1588","LU2328871848.SGD","BK1583"],"gpt_icon":0},{"id":"2514000941","title":"百济神州回应原大中华区CFO离职：将尽快启动其继任者的招聘","url":"https://stock-news.laohu8.com/highlight/detail?id=2514000941","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514000941?lang=zh_cn&edition=fundamental","pubTime":"2025-02-26 16:10","pubTimestamp":1740557408,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["NVS","ONC","LU0588546209.SGD","IE00B4R5TH58.HKD","BK1588","IE00BJT1NW94.SGD","IE00B2B36J28.USD","BK4578","BK1161","BK4139","IE0002141913.USD","BK1500","BK1583","LU1969619763.USD","688235","BK0239","BK4585","IE0009355771.USD","06160","LU0307460666.USD","BK4007","LU2328871848.SGD","BK4532","BK4588","LU0211331839.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD"],"gpt_icon":0},{"id":"2514888885","title":"230元/股！百济神州股价再创新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2514888885","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514888885?lang=zh_cn&edition=fundamental","pubTime":"2025-02-26 16:10","pubTimestamp":1740557400,"startTime":"0","endTime":"0","summary":"2月26日，百济神州股价盘中最高触及230元/股，涨幅超4%，创历史新高。核心产品泽布替尼（百悦泽）2024年前三季度全球销售额达18.16亿美元，同比增长107%，占公司总营收67.7%。截至2024年三季度，公司累计未弥补亏损达613.75亿元，研发及销售费用分别为101.7亿元和63.48亿元，均居A股药企前列。泽布替尼已在70余个国家获批，海外收入占比超70%，其头对头击败强生伊布替尼的临床数据进一步巩固技术领先地位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226161112989348c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226161112989348c2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","LU0588546209.SGD","ONC","LU2328871848.SGD","688235","BK1588","LU1969619763.USD","LU0307460666.USD","BK1500","BK1583","BK1161"],"gpt_icon":0},{"id":"2514002090","title":"百济神州回应原大中华区CFO离职：将尽快启动其继任者的招聘","url":"https://stock-news.laohu8.com/highlight/detail?id=2514002090","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514002090?lang=zh_cn&edition=fundamental","pubTime":"2025-02-26 16:09","pubTimestamp":1740557367,"startTime":"0","endTime":"0","summary":"2月26日，有媒体报道称百济神州的大中华区首席财务官（CFO）兼全球技术运营财务负责人黄智已经离职。公开资料显示，加入百济神州之前，黄智在2007年至2020年期间就职于诺华。2月26日下午，《每日经济新闻》记者从百济神州方面得知，公司原大中华区首席财务官兼全球技术运营财务负责人黄智（EricHuang）确于近日离任寻求外部发展机会。公司将尽快启动其继任者的招聘。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202502263330282672.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502263330282672.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1969619763.USD","06160","BK1500","LU2328871848.SGD","BK1583","BK1161","BK4139","LU0307460666.USD","ONC","BK1588","LU0588546209.SGD"],"gpt_icon":0},{"id":"2514883004","title":"百济神州确认原大中华区首席财务官兼全球技术运营财务负责人黄智离职","url":"https://stock-news.laohu8.com/highlight/detail?id=2514883004","media":"南方财经网","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514883004?lang=zh_cn&edition=fundamental","pubTime":"2025-02-26 15:22","pubTimestamp":1740554523,"startTime":"0","endTime":"0","summary":"南方财经2月26日电，据界面新闻，百济神州向记者确认，百济神州原大中华区首席财务官兼全球技术运营财务负责人黄智（EricHuang）于近日离任寻求外部发展机会。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502263330239396.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ONC","LU0307460666.USD","BK1161","LU0588546209.SGD","LU1969619763.USD","BK1500","BK1583","06160","BK1588","BK4139","LU2328871848.SGD"],"gpt_icon":0},{"id":"2514009350","title":"百济神州大中华区CFO黄智已经离职","url":"https://stock-news.laohu8.com/highlight/detail?id=2514009350","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514009350?lang=zh_cn&edition=fundamental","pubTime":"2025-02-26 15:01","pubTimestamp":1740553261,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK4139","06160","IE0002141913.USD","BK1588","BK4578","BK1583","LU2328871848.SGD","NVS","ONC","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0211331839.USD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","BK4585","BK1161","BK4532","IE0009355771.USD","LU0588546209.SGD","IE00B4R5TH58.HKD","BK1500","BK0239","LU1969619763.USD","BK4007","BK4588","688235","LU0307460666.USD"],"gpt_icon":0},{"id":"2514009047","title":"百济神州大中华区CFO黄智已经离职","url":"https://stock-news.laohu8.com/highlight/detail?id=2514009047","media":"第一财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514009047?lang=zh_cn&edition=fundamental","pubTime":"2025-02-26 15:00","pubTimestamp":1740553241,"startTime":"0","endTime":"0","summary":"【百济神州大中华区CFO黄智已经离职】2月26日，接近百济神州的人士透露，百济神州的大中华区首席财务官兼全球技术运营财务负责人黄智已经离职。加入百济神州之前，黄智在2007年至2020年期间就职于诺华。目前百济神州全球CFO为Aaron Rosenberg。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://hk.eastmoney.com/a/202502263330220729.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://hk.eastmoney.com/a/202502263330220729.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06160","LU0588546209.SGD","ONC","BK1588","LU1969619763.USD","LU2328871848.SGD","LU0307460666.USD","BK1583","BK1161","BK4139","BK1500"],"gpt_icon":0},{"id":"2514900875","title":"港股概念追踪|百济神州成为国内“创新药一哥”  机构看好创新药2025年估值修复（附概念股）","url":"https://stock-news.laohu8.com/highlight/detail?id=2514900875","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514900875?lang=zh_cn&edition=fundamental","pubTime":"2025-02-26 13:53","pubTimestamp":1740549201,"startTime":"0","endTime":"0","summary":"2月21日，百济神州以27亿元市值差距超越恒瑞医药，成为“创新药一哥”。百济神州的创新药收入增长迅猛，其BTK抑制剂泽布替尼全球销售额突出。百济神州市值新高有业绩支撑，预计2025年全年经营利润为正。国金证券发布研究报告称，建议继续贯彻AI医药+创新药2025年医药投资两大布局主线。该行表示，看好行业估值修复。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1254498.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU2328871848.SGD","IE00BPRC5H50.USD","LU1794554557.SGD","BK1583","159992","LU0417516571.SGD","BK4139","06160","LU2488822045.USD","BK1500","IE00B5MMRT66.SGD","LU0348783233.USD","LU1720050803.USD","LU0348784397.USD","IE00B543WZ88.USD","09926","06978","HSTECH","ONC","LU1969619763.USD","01801","688235","BK1589","BK1588","HSCEI","BK1574","BK0239","LU0307460666.USD","YANG","LU0588546209.SGD"],"gpt_icon":1},{"id":"2514070291","title":"【创新药板块大幅走高 君实生物等多股涨超10%】百济神州涨近4%，创历史新高，君实生物、博瑞医药、益方生物涨超10%，诺诚健华、新诺威、荣昌生物、昭衍新药等多股涨逾5%。消息面上，据统计，2024年全年创新药企License-out交易首付款总额（31.6亿美元）甚至超过了创新药研发融资的总额（27.1亿美元），创新药出海成为国内创新药企核心动力。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514070291","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514070291?lang=zh_cn&edition=fundamental","pubTime":"2025-02-26 13:41","pubTimestamp":1740548461,"startTime":"0","endTime":"0","summary":"百济神州涨近4%，创历史新高，君实生物、博瑞医药、益方生物涨超10%，诺诚健华、新诺威、荣昌生物、昭衍新药等多股涨逾5%。消息面上，据统计，2024年全年创新药企License-out交易首付款总额（31.6亿美元）甚至超过了创新药研发融资的总额（27.1亿美元），创新药出海成为国内创新药企核心动力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/26134148395945.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["09969","BK1583","LU1064131003.USD","LU1969619763.USD","BK4139","06127","688166","688180","159992","BK1500","06160","BK0226","603127","ONC","01877","BK1161","688235","300765","LU0588546209.SGD","688428","BK0239","BK1588","06978","688331","BK1576","LU2328871848.SGD","09995","BK1574","LU2148510915.USD","BK1515","BK0216","LU1064130708.USD","688382","BK1141","LU0307460666.USD"],"gpt_icon":0},{"id":"2514784033","title":"创新药企业业绩有望显著改善，诺诚健华、百济神州等被机构推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2514784033","media":"中国制药网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514784033?lang=zh_cn&edition=fundamental","pubTime":"2025-02-25 11:06","pubTimestamp":1740452783,"startTime":"0","endTime":"0","summary":"具备差异化管线、国际化能力强和商业化效率高的企业值得关注，如 诺诚健华 、 百济神州 。据悉，近期百济神州发布公告，预计将实现2025年全年经营利润为正。据了解，近年来，创新药备受国家利好政策支持。在利好政策的推动下，国内创新药有望迎来 黄金 发展周期。受益标的包括 恒瑞医药 、 百利天恒 、诺诚健华、百济神州、科伦博泰、 信达生物 、 热景生物 、 泓博医药 、 成都先导 等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225112919a252c3eb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225112919a252c3eb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0588546209.SGD","LU1969619763.USD","06160","09969","BK1574","BK1500","06978","ONC","LU0307460666.USD","688428","BK1161","BK1583","688235","LU2328871848.SGD","BK1588"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":8,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"date":"2025-05-07","symbol":"ONC","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":-0.74,"defaultRemindTime":1746604800000,"name":null,"time":"盘前","dateTimestamp":1746590400000,"actualEps":null},{"market":"US","date":"2025-02-27","symbol":"ONC","fiscalQuarterEnding":"2024/12","expectedEps":-0.88,"name":null,"time":"盘前","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-1.43},{"market":"US","date":"2024-11-12","symbol":"ONC","fiscalQuarterEnding":"2024/09","expectedEps":-0.88,"name":null,"time":"盘前","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-08-07","symbol":"ONC","fiscalQuarterEnding":"2024/06","expectedEps":-2.1,"name":null,"time":"盘前","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-05-11","symbol":"ONC","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1715400000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2727,"buy":0.6818,"hold":0.0455,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6818,"analysts":22,"updateTime":1744084800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2025-04-17","current":-38.113584,"percent":0.422535,"low":-46.072488,"twenty":-42.748137,"median":-33.549429,"eighty":-28.784295,"high":-22.805663,"avg":-34.842528,"sd":7.324243,"marketCap":24575105056},"quantilePoints":[{"date":"2025-01-03","current":-23.85925,"twenty":-23.85925,"median":-23.85925,"eighty":-23.85925,"marketCap":19590153584},{"date":"2025-01-10","current":-23.169003,"twenty":-23.588216,"median":-23.51181,"eighty":-23.096335,"marketCap":18938568040},{"date":"2025-01-17","current":-26.770744,"twenty":-26.217794,"median":-23.689854,"eighty":-23.142836,"marketCap":21882666138},{"date":"2025-01-24","current":-28.798988,"twenty":-27.60701,"median":-25.13119,"eighty":-23.374687,"marketCap":23683664763},{"date":"2025-01-31","current":-29.253094,"twenty":-28.895055,"median":-26.770744,"eighty":-23.516999,"marketCap":24179205805},{"date":"2025-02-07","current":-29.699946,"twenty":-29.114029,"median":-28.456686,"eighty":-23.723733,"marketCap":24422582437},{"date":"2025-02-14","current":-29.279798,"twenty":-29.132261,"median":-28.781271,"eighty":-23.9826,"marketCap":24061904635},{"date":"2025-02-21","current":-31.546239,"twenty":-29.269116,"median":-28.798062,"eighty":-24.917918,"marketCap":26058437677},{"date":"2025-02-28","current":-46.072488,"twenty":-30.312806,"median":-28.916244,"eighty":-26.238043,"marketCap":29706894943},{"date":"2025-03-07","current":-42.702936,"twenty":-33.205878,"median":-29.060335,"eighty":-26.487572,"marketCap":27534255325},{"date":"2025-03-14","current":-42.304107,"twenty":-40.627279,"median":-29.228112,"eighty":-26.926934,"marketCap":27277096074},{"date":"2025-03-21","current":-43.63686,"twenty":-41.989697,"median":-29.279798,"eighty":-27.60701,"marketCap":28136436571},{"date":"2025-03-28","current":-43.795471,"twenty":-42.273573,"median":-29.808923,"eighty":-28.393975,"marketCap":28238706493},{"date":"2025-04-04","current":-44.082326,"twenty":-43.290212,"median":-30.877376,"eighty":-28.597906,"marketCap":28423666794},{"date":"2025-04-11","current":-34.741183,"twenty":-42.946887,"median":-33.164233,"eighty":-28.695114,"marketCap":22400628140},{"date":"2025-04-17","current":-38.113584,"twenty":-42.748137,"median":-33.549429,"eighty":-28.784295,"marketCap":24575105056}],"updateTime":1745185814973}}}